论文部分内容阅读
卵巢癌是妇科常见的恶性肿瘤,化疗耐药是影响卵巢癌患者预后的主要原因。近年基因组工程从DNA和RNA水平阐明了多药耐药的遗传基础,但是,未能精确描述肿瘤耐药细胞在蛋白质水平所发生的一切。肿瘤蛋白质组学的出现及其研究技术的发展和完善使在蛋白质整体水平上研究多药耐药产生的机制成为可能。现结合国外近5年的研究,对利用蛋白质组学技术筛选新的卵巢癌多药耐药靶向蛋白作一综述。
Ovarian cancer is a common gynecological malignancy, chemotherapy resistance is the main reason affecting the prognosis of patients with ovarian cancer. In recent years, genomic engineering has elucidated the genetic basis of multidrug resistance from the level of DNA and RNA. However, it failed to accurately describe what happens at the protein level of tumor-resistant cells. The emergence of tumor proteomics and the development and improvement of its research technology make it possible to study the mechanism of multidrug resistance in the overall level of protein. Now combined with nearly 5 years of foreign research, the use of proteomics technology screening of new ovarian cancer multidrug-resistant target protein for a review.